Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Total Non-Current Liabilities (2024 - 2025)

Evommune (EVMN) has disclosed Total Non-Current Liabilities for 2 consecutive years, with $10.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities changed N/A to $10.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $10.4 million, a N/A change, with the full-year FY2024 number at $28.0 million, changed N/A from a year prior.
  • Total Non-Current Liabilities was $10.4 million for Q3 2025 at Evommune, down from $28.0 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $28.0 million in Q4 2024 to a low of $10.4 million in Q3 2025.